Analyst Price Targets — EVOK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 28, 2024 2:21 pm | Yale Jen | Laidlaw | $18.00 | $7.08 | StreetInsider | Laidlaw Reiterates Buy Rating on Evoke Pharma (EVOK) |
Latest News for EVOK
Evoke H1 Earnings Call Highlights
Evoke LON: EVOK reported stable first-half revenue and lower adjusted EBITDA as increased gaming duties, particularly in the U.K., added a £46 million year-on-year cost headwind. Management said mitigation efforts, including more efficient marketing, cost savings and retail estate changes, offset more than half of the impact during the period.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EVOK.
U.S. House Trading
No House trades found for EVOK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.